Cryoservice manager runs the extra mile for Cancer Research
David Bryant completes 145-mile Grand Union Canal Run from Birmingham to London
David Bryant, Cryoservice's business manager for science and industry, took 39 hours 15 minutes to complete the distance, running without sleep or a reasonable break.
‘The race is extremely challenging with only 40% of the starting line up normally finishing, so a hard training regime was required even to be in with a chance of reaching London,’ he said.
‘What kept me going was the knowledge that so many people had sponsored me and that the money raised would be going to a good cause.’
Bryant raised £3,350 for Cancer Research and came 16th.
Cryoservice, a supplier of specialist gases for science, leisure and industry, based in Worcester, UK, is a long-term business partner of Cancer Research UK and was recently short-listed for Supplier of the Year award, in recognition of its commitment and support of the organisation.
You may also like
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Logistics
Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa
Initial implementation begins in Uganda, Kenya and Côte d'Ivoire, connecting screening, diagnosis, referral and long-term management into a unified pathway as the continent accounts for nearly 80% of the global disease burden
Research & Development
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency